Fremanezumab is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Rosacea. According to GlobalData, Phase I drugs for Rosacea have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Fremanezumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fremanezumab overview

Fremanezumab (Ajovy / Adjovi) is a fully humanized IgG2a/kappa monoclonal antibody  acts as an anti-migraine agent. It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. It is formulated as solution for the subcutaneous route of administration. Ajovy is indicated for the preventive treatment of migraine in adults who have at least 4 migraine days per month.

Fremanezumab (TEV-48125, LBR-101, PF-04427429) is under development for the treatment of migraine in children and adolescents and rosacea. The drug candidate is administered through intravenous and subcutaneous routes. It is an anti-CGRP humanized monoclonal antibody.

It was under development for the treatment of fibromyalgia, chronic and episodic migraine, post-traumatic headache (traumatic pain), unspecified indications, vasomotor symptoms of menopause (menopausal hot flashes), interstitial cystitis (bladder pain syndrome) and cluster headache.

For a complete picture of Fremanezumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.